SCHEMBL1844987

SCHEMBL1844987

OC1CCCN1Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.56
GBA1 P04062 1/20 0.51
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
SPHK2 Q9NRA0 2/20 0.47
SPHK1 Q9NYA1 2/20 0.47
MAPT P10636 1/20 0.46
SIGMAR1 Q99720 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2433049 1.00 ALDH1A1 (0.56) ALDH1A1GBA1CYP1A2CYP3A4CYP2D6
Methane SCHEMBL6969354 0.98 ALDH1A1 (0.54) ALDH1A1GBA1CYP1A2CYP3A4CYP2D6
SCHEMBL2230942 0.95 GBA1 (0.50) ALDH1A1GBA1
Methane SCHEMBL7288556 0.93 GBA1 (0.49) ALDH1A1GBA1
SCHEMBL4869898 0.89 GBA1 (0.58) ALDH1A1GBA1MAPTSIGMAR1
Methane SCHEMBL28108223 0.87 GBA1 (0.57) ALDH1A1GBA1MAPTSIGMAR1
SCHEMBL27510453 0.82 GBA1 (0.54) GBA1CYP1A2CYP3A4CYP2D6SIGMAR1
SCHEMBL17062136 0.80 MAPT (0.53) ALDH1A1GBA1MAPT
SCHEMBL17062432 0.80 MAPT (0.53) ALDH1A1GBA1MAPT
SCHEMBL9417740 0.79 CYP1A2 (0.49) ALDH1A1GBA1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137220-B1 AROMATIC URETHANE ACRYLATES HAVING A HIGH REFRACTIVE INDEX COVESTRO DEUTSCHLAND AG (DE) 2017-10-18 EP disclosed
CN-101906060-B Process for the preparation of N-substituted 3-aminomethylpyrrolidines ACESYS PHARMATECH NANJING CO LTD 2012-07-04 CN disclosed
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-20110190511-A1 Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto IM&T RESEARCH, INC. (US) 2011-08-04 US disclosed
US-7981987-B2 Aromatic urethane acrylates having a high refractive index BAYER MATERIALSCIENCE AG (DE) 2011-07-19 US disclosed
EP-2323974-A1 METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO Ube Industries, Ltd. (JP) 2011-05-25 EP disclosed
CN-101906060-A Process for the preparation of N-substituted 3-aminomethylpyrrolidines ACESYS PHARMATECH NANJING CO LTD 2010-12-08 CN disclosed
US-20100152463-A1 Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto IM&T RESEARCH, INC. (US) 2010-06-17 US disclosed
WO-2010022001-A1 METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO IM&T RESEARCH, INC. (US) 2010-02-25 WO disclosed
EP-2137220-A1 AROMATIC URETHANE ACRYLATES HAVING A HIGH REFRACTIVE INDEX Bayer MaterialScience AG (DE) 2009-12-30 EP disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed
CN-1391473-A VLA-4 inhibitor compounds DAIICHI SEIYAKU CO (JP) 2003-01-15 CN disclosed
US-6388083-B2 ANTAGONIST TO SUBSTANCE P RECEPTORS MERCK & CO., INC. 2002-05-14 US disclosed
US-20020019532-A1 Process for the synthesis of (2S)-phenyl-3-piperidone MERCK & CO., INC. 2002-02-14 US disclosed
US-4212822-A Preparation of o-dialkylaminomethylphenols BAYER AKTIENGESELLSCHAFT (DE) 1980-07-15 US disclosed
US-4208423-A Anticholinergic bronchodilators SYNTEX INC. (US) 1980-06-17 US disclosed
EP-0012071-A1 Azoniaspiro derivatives, process for their preparation and pharmaceutical compositions containing them SYNTEX (U.S.A.) INC. (US) 1980-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 ALDH1A1 146/4885GBA1 1178/4885CYP1A2 2573/4885
US-20100152463-A1 Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto PFAS, AGPS, FDPS ALDH1A1 1367/4885GBA1 145/4885CYP1A2 1113/4885
US-20110190511-A1 Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto PFAS, AGPS, FDPS ALDH1A1 1500/4885GBA1 99/4885CYP1A2 838/4885
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 ALDH1A1 981/4885GBA1 1252/4885CYP1A2 2327/4885
US-20020019532-A1 Process for the synthesis of (2S)-phenyl-3-piperidone DHPS, NPEPPS, ALDH18A1 ALDH1A1 160/4885GBA1 376/4885CYP1A2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.